Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus irinotecan in previously treated metastatic colorectal cancer selected by KRAS and EGFR intron 1 CA repeats
2008-003160-19Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and irinotecan in colorectal cancer (CRC) and colon adenocarcinoma, sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Response rate. Started Nov 2008; status: active.
02
Drugs
cetuximabirinotecan
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on 2008-003160-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003160-19.